文献速递肝胆胰外科围术期管理与 ERAS

新辅助治疗时代胰腺癌外科策略的重塑:挑战与机遇

[Reshaping surgical strategies for pancreatic cancer in the era of neoadjuvant therapy: challenges and opportunities].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2026-01-01

随着新辅助治疗在胰腺癌中广泛应用,传统以手术为中心的治疗范式正深刻转变。手术适应证、时机及预期获益需在新框架下重新界定,可切除性评估从解剖学判断转向融合肿瘤生物学与治疗反应的综合决策。外科医师角色向多学科决策核心演变,核心目标为以长期生存获益为导向的精准外科决策。

要点

  • 新辅助治疗推动可切除性评估从解剖学判断转向整合肿瘤生物学与治疗反应的综合决策。
  • 外科策略聚焦「为谁手术、何时手术、如何手术」,而非单纯「是否手术」。
  • 外科医师角色由技术执行者向多学科协作中的决策核心转变。

核心结论

  • 新辅助治疗时代胰腺癌外科策略的重塑聚焦于为谁手术、何时手术、如何手术,核心目标是实现以患者长期生存获益为导向的精准外科决策。

主要发现

  • 新辅助治疗通过提高全程治疗完成度、实现生物学筛选及优化外科干预对象,推动可切除性评估模式转变。
  • 外科治疗面临适应证边界模糊、手术时机判断复杂化、技术难度与围手术期风险变化及传统评价体系滞后等多重挑战。

临床怎么用

  • 外科医师应在多学科协作中承担决策核心角色,参与新辅助治疗背景下手术适应证、时机与方式的综合判断。
  • 手术策略应趋于精细化,并推动手术技术与评估理念的持续创新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the widespread adoption of neoadjuvant therapy in pancreatic cancer, the traditional surgery-centered treatment paradigm is undergoing a profound shift. Against the background of upfront systemic therapy, surgery no longer naturally occupies the starting point of the treatment sequence; instead, its indications, timing, and expected benefits must be re-evaluated and redefined within the new treatment framework. By improving completion of the entire treatment course, enabling biological selection, and optimizing patient selection for surgical intervention, neoadjuvant therapy has driven a shift in resectability assessment from a purely anatomical judgment toward a comprehensive decision-making model that integrates tumor biology and treatment response. Nevertheless, surgical practice faces multiple challenges, including blurred boundaries of surgical indications, greater complexity in determining the optimal timing of surgery, evolving technical difficulty and perioperative risk, and the limitations of traditional evaluation frameworks. On this basis, the role of surgeons is evolving from executors of surgical techniques to central decision-makers within multidisciplinary teams, accompanied by increasing refinement of surgical strategies and ongoing innovation in surgical techniques and assessment concepts. Overall, the reshaping of surgical strategies for pancreatic cancer in the era of neoadjuvant therapy is not centered on the binary question of whether to operate, but rather on determining for whom, when, and how surgery should be performed, with the ultimate goal of achieving precise surgical decision-making oriented toward long-term survival benefit for patients. 随着新辅助治疗在胰腺癌治疗中的广泛应用,传统以手术为中心的治疗范式正经历深刻转变。在系统治疗前移的背景下,外科手术不再占据治疗流程的起始环节,其适应证、实施时机及预期获益均需在新的治疗框架下重新审视与界定。新辅助治疗通过提高全程治疗完成度、实现生物学筛选及优化外科干预对象,推动可切除性评估由单纯的解剖学判断向融合肿瘤生物学行为与治疗反应的综合决策模式转变。然而,外科治疗亦面临适应证边界模糊、手术时机判断复杂化、技术难度与围手术期风险变化以及传统评价体系滞后等多重挑战。在此基础上,外科医师的角色正由手术技术执行者向多学科协作模式中的决策核心转变,手术策略趋于精细化,手术技术与评估理念不断创新。总体而言,新辅助治疗时代胰腺癌外科策略的重塑,并非围绕“是否手术”,而是聚焦于“为谁手术、何时手术、如何手术”,其核心目标在于实现以患者长期生存获益为导向的精准外科决策。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. He J, Li Z. [Reshaping surgical strategies for pancreatic cancer in the era of neoadjuvant therapy: challenges and opportunities]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 42350887. doi:10.3760/cma.j.cn112139-20260311-00097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。